34
Participants
Start Date
May 31, 2007
Primary Completion Date
December 31, 2010
Study Completion Date
May 31, 2011
Sorafenib
Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
Princess Margaret Hospital, Toronto
University Health Network, Toronto
OTHER